Skip to content

CJC-1295 (no DAC)

CJC-1295 without DAC — also referred to as Modified GRF 1-29 — is a short-acting synthetic 29-amino acid analog of GHRH with a molecular weight of approximately 3,367 Da. Unlike the DAC-conjugated variant, this peptide lacks the maleimidopropionic acid-maleimide group, resulting in a significantly shorter plasma half-life (approximately 30 minutes) and a pulsatile GH secretion profile that more closely mimics physiological GHRH signaling. The parent GRF 1-29 CAS is 83930-13-6; CJC-1295 (no DAC) includes four amino acid substitutions that enhance stability and receptor affinity.

Technical Specifications

Property Value
CAS Number N/A (modified peptide; parent GRF 1-29 CAS 83930-13-6)
Molecular Formula C₁₅²H₂₄₀N₄₄O₄₂
Molecular Weight ~3,367 Da
Purity ≥99% (HPLC-verified)
Appearance Lyophilized white powder
Solubility Soluble in aqueous buffers and sterile water
Storage -20°C (lyophilized), 2–8°C (reconstituted)

Mechanism of Action

CJC-1295 without DAC binds with high affinity to the GHRH receptor (GHRH-R) on anterior pituitary somatotroph cells, stimulating Gαs-mediated adenylyl cyclase activation, cAMP elevation, and PKA-dependent calcium channel opening. This triggers the pulsatile exocytosis of pre-formed growth hormone secretory granules. The four key modifications from native GRF 1-29 — Tyr¹ substitution, D-Ala² (which confers DPP-4 resistance), Gln⁸, and Arg²⁹-NH₂ amidation — collectively extend the peptide's half-life from the native ~2–3 minutes to approximately 30 minutes while maintaining full receptor agonist potency. Because the peptide is rapidly cleared between doses, research protocols produce discrete GH pulses rather than continuous elevation, preserving physiological negative feedback through somatostatin and IGF-1. This pulsatile profile is critical for maintaining GHRH receptor sensitivity and avoiding the GH desensitization observed with continuous agonist exposure.

Research Applications

  • Primary: Pulsatile growth hormone secretion research — GHRH receptor pharmacology, GH pulse dynamics
  • Secondary: Somatostatin/GHRH feedback loop studies, GH/IGF-1 axis circadian rhythm research, combination secretagogue protocols (co-administration with GHRP-2 or ipamorelin)
  • Model Systems: In vitro (pituitary cell cultures, GHRH-R radioligand binding), in vivo (GH pulse profiling in rodent and porcine models)

Quality Control & Analytical Methods

  • HPLC: ≥99% purity verification at 214/220 nm (C18 reversed-phase column)
  • Mass Spectrometry: ESI-MS for molecular weight confirmation (~3,367 ±1.0 Da)
  • Peptide Content: Amino acid analysis (AAA) for net peptide content determination
  • Endotoxin: <1 EU/mg (LAL assay)
  • TFA Content: <1% (ion chromatography)

Stability & Storage

Condition Stability
-20°C (lyophilized) 24 months
4°C (lyophilized) 6 months
25°C (lyophilized) 1 month
Reconstituted (4°C) 7 days
Reconstituted (-20°C) 30 days

Key Research References

  • Teichman et al. (2006) — Prolonged stimulation of growth hormone and insulin-like growth factor-1 secretion by CJC-1295. J Clin Endocrinol Metab. PMID: 16434580
  • Sackmann-Sala et al. (2009) — Pharmacokinetics and pharmacodynamics of CJC-1295. Growth Horm IGF Res. PMID: 19428564
  • Walker et al. (2010) — Pulsatile vs. continuous GHRH receptor activation: implications for GH axis research. Endocr Rev. PMID: 20501671

Source & Purchase

For researchers requiring research-grade CJC 1295 NO DAC with full analytical documentation including HPLC, LC-MS, and Certificate of Analysis, visit the HK Peptides product page for specifications, bulk pricing, and ordering.

View CJC 1295 NO DAC Product →

FAQ

Q: What purity level is standard for CJC-1295 (no DAC)? A: HK Peptides supplies CJC-1295 (no DAC) at ≥99% purity by HPLC with full COA documentation.

Q: How should CJC-1295 (no DAC) be stored for research use? A: Lyophilized CJC-1295 (no DAC) should be stored at -20°C. Reconstituted solutions at 4°C for short-term use (up to 7 days).